| 1 |
Lamba N, Kearney RB, Catalano PJ, et al. Population-based estimates of survival among elderly patients with brain metastases[J]. Neuro Oncol, 2021, 23(4): 661-676.
|
| 2 |
Palicelli A, Croci S, Bisagni A, et al. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)[J]. Int J Mol Sci, 2021.
|
| 3 |
陈立如, 刘亮, 彭雷, 等. 单孔胸腔镜左肺下叶袖式切除术:新辅助免疫化疗后手术[J]. 中华胸部外科电子杂志, 2023, 10(4): 22833-22233.
|
| 4 |
Gray JE, Saltos A, Tanvetyanon T, et al. Phase Ⅰ/Ⅰb Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer[J]. Clin Cancer Res, 2019, 25(22): 6623-6632.
|
| 5 |
Argiris A, Lee JW, Stevenson J, et al. Phase Ⅱ randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)[J]. Ann Oncol, 2017, 28(12): 3037-3043.
|
| 6 |
Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations[J]. Eur J Health Econ, 2020, 21(1): 153-164.
|
| 7 |
周娟, 习磊, 赵沙, 等. 肺癌免疫治疗动态监测标志物的研究进展[J]. 中华胸心血管外科杂志, 2018, 34(10): 636-640.
|
| 8 |
Suwinski R. Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer[J]. J Thorac Dis, 2021, 13(5): 3315-3322.
|
| 9 |
Lu R, Wang Z, Tian W, et al. A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer[J]. Sci Rep, 2025, 15(1): 7036.
|
| 10 |
Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227[J]. J Clin Oncol, 2023, 41(6): 1200-1212.
|
| 11 |
West HJ, McCleland M, Cappuzzo F, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase Ⅲ IMpower150 trial[J]. J Immunother Cancer, 2022, 10(2): e003027.
|
| 12 |
Buriolla S, Pelizzari G, Corvaja C, et al. Immunotherapy in NSCLC Patients with Brain Metastases[J]. Int J Mol Sci, 2022, 23(13): 7068.
|